| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $441,691 | 13 | 100 |
| Douglas Earl Martin | SVP, General Counsel | 0 | $0 | 1 | $10,951 | $-10,951 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | 0 | $0 | 2 | $11,798 | $-11,798 |
| Yoshiyama Annie | SVP, Finance | 0 | $0 | 1 | $13,537 | $-13,537 |
| MOORE TIMOTHY L. | Chief Technical Officer | 0 | $0 | 1 | $25,216 | $-25,216 |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 0 | $0 | 2 | $53,713 | $-53,713 |
| Roberts Zachary | EVP of R&D | 0 | $0 | 2 | $72,994 | $-72,994 |
| MESSEMER DEBORAH M. | director | 0 | $0 | 2 | $84,727 | $-84,727 |
| Chang David D | President and CEO | 0 | $0 | 2 | $168,754 | $-168,754 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Allogene Therapeutics, Inc. have bought $0 and sold $441,691 worth of Allogene Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Allogene Therapeutics, Inc. have bought $3.57M and sold $1.16M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,724,137 shares for transaction amount of $5M was made by Belldegrun Arie (director) on 2024‑05‑16.
| 2026-01-21 | Sale | Roberts Zachary | EVP of R&D | 26,269 0.0114% | $1.56 | $40,980 | +10.26% | |
| 2025-11-17 | Sale | Beneski Benjamin Machinas | SVP, Chief Technical Officer | 786 0.0003% | $1.22 | $959 | +17.07% | |
| 2025-10-21 | Sale | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 36,744 0.0165% | $1.26 | $46,169 | +9.13% | |
| 2025-06-10 | Sale | MESSEMER DEBORAH M. | director | 36,885 0.0164% | $1.42 | $52,377 | -15.07% | |
| 2025-04-21 | Sale | Yoshiyama Annie | SVP, Finance | 9,601 0.0044% | $1.41 | $13,537 | -12.68% | |
| 2025-03-14 | Sale | Chang David D | President and CEO | 46,668 0.0225% | $1.96 | $91,469 | -34.54% | |
| 2025-03-14 | Sale | Beneski Benjamin Machinas | SVP, Chief Technical Officer | 5,488 0.0027% | $1.98 | $10,839 | -34.54% | |
| 2025-02-18 | Sale | MESSEMER DEBORAH M. | director | 13,313 0.0076% | $2.43 | $32,351 | -54.58% | |
| 2025-02-03 | Sale | Chang David D | President and CEO | 46,003 0.0205% | $1.68 | $77,285 | -20.66% | |
| 2025-02-03 | Sale | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 4,361 0.002% | $1.73 | $7,545 | -20.66% | |
| 2025-02-03 | Sale | Roberts Zachary | EVP of R&D | 18,832 0.0085% | $1.70 | $32,014 | -20.66% | |
| 2025-02-03 | Sale | Douglas Earl Martin | SVP, General Counsel | 6,404 0.0029% | $1.71 | $10,951 | -20.66% | |
| 2025-02-03 | Sale | MOORE TIMOTHY L. | Chief Technical Officer | 14,746 0.0067% | $1.71 | $25,216 | -20.66% | |
| 2025-01-21 | Sale | Roberts Zachary | EVP of R&D | 27,199 0.0125% | $1.78 | $48,414 | -27.17% | |
| 2024-12-09 | Sale | MESSEMER DEBORAH M. | director | 9,136 0.0042% | $2.18 | $19,916 | -40.53% | |
| 2024-12-05 | Sale | Humer Franz B | director | 9,221 0.0044% | $2.16 | $19,917 | -36.92% | |
| 2024-06-18 | Sale | MESSEMER DEBORAH M. | director | 18,641 0.008% | $2.28 | $42,488 | -3.14% | |
| 2024-05-30 | Sale | Humer Franz B | director | 11,200 0.0051% | $2.34 | $26,181 | -8.33% | |
| 2024-05-16 | Belldegrun Arie | director | 1.72M 0.9747% | $2.90 | $5M | -23.26% | ||
| 2024-01-30 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 190 0.0001% | $3.60 | $683 | -25.56% |
| Chang David D | President and CEO | 5276569 2.348% | $9.08M | 1 | 5 | +2.3% |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 1276796 0.5681% | $2.2M | 1 | 2 | <0.0001% |
| Roberts Zachary | EVP of R&D | 616866 0.2745% | $1.06M | 0 | 3 | |
| Douglas Earl Martin | SVP, General Counsel | 587848 0.2616% | $1.01M | 0 | 1 | |
| MOORE TIMOTHY L. | Chief Technical Officer | 250713 0.1116% | $431,226.36 | 0 | 1 | |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | 217721 0.0969% | $374,480.12 | 0 | 2 | |
| Yoshiyama Annie | SVP, Finance | 130663 0.0581% | $224,740.36 | 0 | 1 | |
| MESSEMER DEBORAH M. | director | 107431 0.0478% | $184,781.32 | 0 | 5 | |
| PFIZER INC | 10 percent owner | 22032040 9.8038% | $37.9M | 1 | 0 | +2.3% |
| TPG Group Holdings (SBS) Advisors, Inc. | 10 percent owner | 18716306 8.3283% | $32.19M | 1 | 17 | +2.3% |
| Belldegrun Arie | director | 1724137 0.7672% | $2.97M | 4 | 0 | <0.0001% |
| Bhavnagri Veer | General Counsel | 577677 0.2571% | $993,604.44 | 0 | 16 | |
| Amado Rafael | EVP of R&D and CMO | 540257 0.2404% | $929,242.04 | 0 | 9 | |
| Humer Franz B | director | 307507 0.1368% | $528,912.04 | 1 | 2 | +2.3% |
| Kazam Joshua A | director | 258885 0.1152% | $445,282.20 | 1 | 0 | <0.0001% |
| WITTE OWEN N. | 218271 0.0971% | $375,426.12 | 1 | 5 | +2.3% | |
| MOORE ALISON | Chief Technical Officer | 120430 0.0536% | $207,139.60 | 0 | 14 | |
| SCHMIDT ERIC THOMAS | Chief Financial Officer | 100546 0.0447% | $172,939.12 | 0 | 8 | |
| Mayo Stephen | director | 25328 0.0113% | $43,564.16 | 0 | 1 |
$5,960,789 | 91 | -7.17% | $352.88M | |
$5,911,307 | 70 | -1.38% | $386.24M | |
$54,836,085 | 68 | -0.52% | $371.98M | |
$17,468,215 | 46 | 18.85% | $443.18M | |
$63,049,419 | 31 | 2.87% | $344.2M | |
$74,231,875 | 30 | 40.62% | $436.85M | |
$54,828,550 | 26 | -13.88% | $360.9M | |
$4,306,464 | 21 | 37.34% | $401.99M | |
$104,137,421 | 15 | 21.28% | $402.59M | |
$65,355,913 | 13 | -3.42% | $360.7M | |
$81,667,942 | 12 | -57.54% | $437.58M | |
Allogene Therapeutics, Inc. (ALLO) | $57,263,116 | 11 | -8.37% | $386.54M |
$603,645 | 8 | 57.40% | $394.72M | |
$166,385 | 7 | -23.62% | $435.08M | |
$43,326,461 | 6 | 16.01% | $374.68M | |
$88,549,962 | 5 | -16.91% | $371.75M | |
$4,745,999 | 5 | -4.91% | $413.55M | |
$4,888,000 | 3 | -20.50% | $344.46M | |
$20,020,000 | 1 | -75.24% | $427.41M |
| Increased Positions | 91 | +61.07% | 22M | +13.54% |
| Decreased Positions | 54 | -36.24% | 44M | -26.87% |
| New Positions | 30 | New | 2M | New |
| Sold Out Positions | 14 | Sold Out | 26M | Sold Out |
| Total Postitions | 186 | +24.83% | 141M | -13.32% |
| Tpg Gp A, Llc | $25,267.00 | 8.32% | 18.72M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $23,645.00 | 7.78% | 17.51M | -382,726 | -2.14% | 2025-09-30 |
| Citadel Advisors Llc | $18,862.00 | 6.21% | 13.97M | +4M | +36.27% | 2025-09-30 |
| Vanguard Group Inc | $12,178.00 | 4.01% | 9.02M | +761,642 | +9.22% | 2025-09-30 |
| Primecap Management Co/Ca/ | $9,557.00 | 3.15% | 7.08M | +1M | +23.78% | 2025-09-30 |
| Woodline Partners Lp | $5,887.00 | 1.94% | 4.36M | 0 | 0% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $5,223.00 | 1.72% | 3.87M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $5,176.00 | 1.7% | 3.83M | +39,058 | +1.03% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $4,965.00 | 1.63% | 3.68M | -353,398 | -8.77% | 2025-09-30 |
| Ubs Group Ag | $4,821.00 | 1.59% | 3.57M | +2M | +75.15% | 2025-09-30 |